US pricing pressure and tariff uncertainty
Continued price erosion in the US generics market and potential tariffs could impact US business growth and margins.
high · analyst_questionAlkem Laboratories Limited — Q4 FY25
Alkem Laboratories reported Q4 FY25 revenue of INR 3,144 crore, up 7.1% YoY, driven by domestic growth of 8.1% and international growth of 7.2%.
bullish
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Operating losses from new ventures
CDMO and medtech businesses are expected to incur combined operating losses of INR 100-125 crore in FY26, weighing on profitability.
medium · management_commentaryTax rate increase post FY26
Tax rate is expected to rise to 35-37% from FY27 as MAT credit is utilized, significantly impacting net profit.
high · management_commentaryAcute business seasonality and NLEM headwinds
Domestic acute business remains vulnerable to seasonal fluctuations and price control under NLEM, which could limit growth.
medium · data_observation